Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors-Reference-Cited by-同舟云学术

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors

Published:2017-07-25 Issue:15 Volume:60 Page:6516-6527
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Brameld Ken A.¹^ORCID,Owens Timothy D.¹,Verner Erik¹,Venetsanakos Eleni¹,Bradshaw J. Michael¹,Phan Vernon T.¹,Tam Danny¹,Leung Kwan¹,Shu Jin¹,LaStant Jacob¹,Loughhead David G.¹,Ton Tony¹,Karr Dane E.¹,Gerritsen Mary E.¹,Goldstein David M.¹,Funk Jens Oliver¹

Affiliation:

1. Principia Biopharma, Inc., 400 East Jamie Court, South San Francisco, California 94080, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00360

Reference44 articles.

1. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

2. Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology

3. The FGF family: biology, pathophysiology and therapy